Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes.
about
Oxidative Reactivity and Cytotoxic Properties of a Platinum(II) Complex Prepared by Outer-Sphere Amide Bond Coupling.Synthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands.Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug deliverySynthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatinConjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexesA novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance.α(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrugComparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cellsSynthetic methods for the preparation of platinum anticancer complexes.Capillary electrophoretic methods in the development of metal-based therapeutics and diagnostics: new methodology and applications.Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs.Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato prodrugs.Synthesis and Analysis of the Structure, Diffusion and Cytotoxicity of Heterocyclic Platinum(IV) Complexes.Highly efficient uptake into cisplatin-resistant cells and the isomerization upon coordinative DNA binding of anticancer tetrazolato-bridged dinuclear platinum(II) complexes.Influence of reducing agents on the cytotoxic activity of platinum(IV) complexes: induction of G2/M arrest, apoptosis and oxidative stress in A2780 and cisplatin resistant A2780cis cell lines.Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.Theoretical investigations and density functional theory based quantitative structure-activity relationships model for novel cytotoxic platinum(IV) complexes.Unsymmetric mono- and dinuclear platinum(IV) complexes featuring an ethylene glycol moiety: synthesis, characterization, and biological activity.Diamminetetrakis(carboxylato)platinum(IV) complexes--synthesis, characterization, and cytotoxicity.Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.Dinuclear Pt(II)-bisphosphonate complexes: a scaffold for multinuclear or different oxidation state platinum drugs.Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues.Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates.Mono-carboxylated diaminedichloridoplatinum(IV) complexes--selective synthesis, characterization, and cytotoxicity.Glycosylated platinum(iv) prodrugs demonstrated significant therapeutic efficacy in cancer cells and minimized side-effects.Platinum(IV) prodrugs with haloacetato ligands in the axial positions can undergo hydrolysis under biologically relevant conditions.Dinuclear Platinum(II) Complexes with Bone-Targeting Groups as Potential Anti-Osteosarcoma Agents.A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers.Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidneyLigation of anti-cancer drugs to self-assembling ultrashort peptides by click chemistry for localized therapyCurrent Developments in Pt(IV) Prodrugs Conjugated with Bioactive LigandsPros and cons of bifunctional platinum(iv) antitumor prodrugs: two are (not always) better than one
P2860
Q30443889-E938DFFA-E38E-4EA8-94CA-1E98F26AEB01Q30607784-7B144D7D-A773-429C-BCF9-F130F98CF907Q33825880-E5F5F416-698F-4530-AD93-062BE663B144Q34028040-99384A4A-C8A2-4FB6-B25B-05606D461FC4Q34060461-EED0A5DD-38B3-41E8-A22D-A00B2612AD27Q34731239-7FB2FA22-B67C-4EF0-9D5A-A818CB3FB529Q35154370-620BC432-65A7-4FBD-A0DB-4C35E0E0FE51Q35154374-DB9B318C-1722-409A-996E-D85803490576Q35334366-9785C2C2-39F3-422A-BA0E-BC00ECF03896Q35981228-661A413F-8FA8-44F9-9F63-63809302CFCEQ36890460-767B230D-17BD-4A91-A8B8-3DB13F35A66EQ37722632-07069D6F-984A-40A9-9B8D-D05F3A695AABQ37997361-2DBF5D5D-F52F-4456-B7A1-BC422AB0482EQ38724009-27D66AFC-5C8A-4B32-842F-DDB5A39CB2EEQ38791841-4874182C-652A-4257-984B-F32BE0648ACAQ38830069-CB8CB618-EEEA-4D38-A62F-9271B0E9CF7DQ38833550-07B48B90-0C00-493B-9736-CB3D06A56EC1Q38864172-9CB9924D-0EC1-4894-9FD2-398344CF1481Q38886580-C77700AF-1529-4954-B3AE-E950096D90F7Q39231857-B544310C-1845-431A-B24F-2779E20536DFQ39235908-88C766C4-9242-4F65-A77D-8FBC68DF7292Q39278942-ECAD64DF-9592-48B4-88EA-4A4BE4CEC4EDQ39298980-69296F87-1C09-441A-AB25-EB78D032522BQ39316883-26B436D1-736D-4B62-B32D-5BAB582C3477Q39372605-7A119C06-4546-48F6-BB17-1C9446E0492FQ39404847-42B4B07C-5123-42E5-B5F4-E18A1758D139Q39405544-B34CC304-5861-4F8A-A137-F506FF01F2C4Q39509386-FE4B3282-89A1-4235-BFD3-4BC3DD822F4BQ42809333-8D1841FE-D7C0-424E-8AA8-C1391C399EC1Q44653144-666E17DF-75BA-406C-A0B9-2905898A4579Q48361294-F88963EE-A247-431A-BA2B-749A12F6A963Q52721390-3E6C56E2-ECF8-4441-8FAF-2D7C331B3A10Q52970552-9CED1AF4-8D46-49D4-BA8F-82872587C146Q57900919-BC869668-A0F9-4F08-8D4E-6375FC836A22Q58063439-24E97E44-331B-4DE6-9F94-3B8009E883CCQ58588998-EC7BB98F-81A3-4926-A687-8EF1C47A9C9CQ59229081-D3D112B9-369A-424C-BC6F-548F8901BAD0
P2860
Tuning of lipophilicity and cytotoxic potency by structural variation of anticancer platinum(IV) complexes.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Tuning of lipophilicity and cy ...... riation of anticancer platinum
@nl
Tuning of lipophilicity and cy ...... cancer platinum(IV) complexes.
@en
type
label
Tuning of lipophilicity and cy ...... riation of anticancer platinum
@nl
Tuning of lipophilicity and cy ...... cancer platinum(IV) complexes.
@en
prefLabel
Tuning of lipophilicity and cy ...... riation of anticancer platinum
@nl
Tuning of lipophilicity and cy ...... cancer platinum(IV) complexes.
@en
P2093
P50
P1476
Tuning of lipophilicity and cy ...... cancer platinum(IV) complexes.
@en
P2093
Anna K Bytzek
Markus Galanski
Seied M Valiahdi
P356
10.1016/J.JINORGBIO.2010.09.006
P50
P577
2010-10-01T00:00:00Z